Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
26/07/202406:00UK RegulatoryAmundi: First Half & Second Quarter 2024 resultsTG:ANIAmundi
26/07/202406:00UK RegulatoryAmundi : Résultats du premier semestre & du deuxième trimestre 2024EU:AMUNAmundi
26/07/202406:00UK RegulatoryAmundi: First Half & Second Quarter 2024 resultsEU:AMUNAmundi
26/07/202406:00UK RegulatoryAmundi : Résultats du premier semestre & du deuxième trimestre 2024TG:ANIAmundi
26/07/202406:00UK RegulatoryUMICORE : RÉSULTATS DU PREMIER SEMESTRE 2024
26/07/202406:00UK RegulatoryCapgemini H1 2024 resultsEU:CAPCapgemini
26/07/202406:00UK RegulatorySignify reports second quarter sales of EUR 1.5 billion, operational profitability of 7.9% and a free cash flow of EUR 51 millionEU:LIGHTSignify NV
26/07/202406:00UK RegulatoryAckermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical companyTG:B3KAckermans and Van Haaren NV
26/07/202406:00UK RegulatoryStart of Day Message
26/07/202406:00UK RegulatoryCapgemini H1 2024 resultsTG:CGMCapgemini
26/07/202406:00UK RegulatoryBekaert: Résultats du premier semestre 2024EU:BEKBNV Bekaert SA
26/07/202406:00UK RegulatorySignify reports second quarter sales of EUR 1.5 billion, operational profitability of 7.9% and a free cash flow of EUR 51 millionXE:G14Signify NV
26/07/202406:00UK RegulatoryAckermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical companyEU:ACKBAckermans and Van Haaren NV
26/07/202406:00UK RegulatoryCapgemini : résultats du 1er semestre 2024TG:CGMCapgemini
26/07/202406:00UK RegulatoryBekaert: 2024 Half Year ResultsEU:BEKBNV Bekaert SA
26/07/202406:00UK RegulatoryAckermans & van Haaren mène une levée de fonds de série B de 60 millions d'euros pour Confo Therapeutics, une société biopharmaceutique belgeTG:B3KAckermans and Van Haaren NV
26/07/202406:00UK RegulatoryVopak reports continued strong results and announces capacity expansions in industrial terminalsEU:VPKKoninklijke Vopak
26/07/202406:00UK RegulatoryUMICORE: HALF YEAR RESULTS 2024
26/07/202406:00UK RegulatoryVopak reports continued strong results and announces capacity expansions in industrial terminalsTG:VPK5Koninklijke Vopak
26/07/202406:00UK RegulatoryCapgemini : résultats du 1er semestre 2024EU:CAPCapgemini
26/07/202406:00UK RegulatoryAckermans & van Haaren mène une levée de fonds de série B de 60 millions d'euros pour Confo Therapeutics, une société biopharmaceutique belgeEU:ACKBAckermans and Van Haaren NV
26/07/202406:00UK RegulatorySignify reports second quarter sales of EUR 1.5 billion, operational profitability of 7.9% and a free cash flow of EUR 51 millionTG:G14Signify NV
26/07/202406:00UK RegulatoryPR Newswire - Start of Day
26/07/202406:00PR Newswire (US)Tokyo Festival Executive Committee Offers Special Tours for Visitors to Enjoy Leading Japanese Contemporary Theater
26/07/202405:54UK RegulatorySPIE - Press release - 2024 Half-Year resultsTG:4SPSpie
26/07/202405:54UK RegulatorySPIE - Communiqué de presse - Résultats du 1er semestre 2024TG:4SPSpie
26/07/202405:54UK RegulatorySPIE - Communiqué de presse - Résultats du 1er semestre 2024EU:SPIESpie
26/07/202405:54UK RegulatorySPIE - Press release - 2024 Half-Year resultsEU:SPIESpie
26/07/202405:51Alliance NewsAlliance NewsUS VP Harris "will not be silent" on Gaza after Netanyahu talks
26/07/202405:51Alliance NewsAlliance NewsPlan to tax super-rich divides at G20 meet in Rio, Brazil